Nonalcoholic Fatty Liver Disease

Subcutaneous pegozafermin at weekly and biweekly doses improved fibrosis at 24 weeks vs. placebo among patients with biopsy-confirmed nonalcoholic steatohepatitis, supporting the therapy’s advancement to phase 3 development, data showed.

Dietary supplementation with resistant starch reduced intrahepatic triglyceride content and may help manage disease by altering gut microbiota among patients with nonalcoholic fatty liver disease, according to data in Cell Metabolism.

Although fibrosis-4 index and NAFLD fibrosis score did not significantly differ in diagnosing advanced fibrosis in nonalcoholic fatty liver disease, fibrosis-4 may be a better screening tool in lean patients, according to a study.

Rates of hepatocellular carcinoma caused by alcohol-related disease and nonalcoholic fatty liver disease are on the rise, especially among Hispanic individuals, according to research in Clinical Gastroenterology and Hepatology.

After nearly a decade of health problems, Steve Harwell, former lead singer and frontman for the band Smash Mouth, died Sept. 4 at age 56, which the band’s manager, Robert Hayes, said was caused by acute liver failure.

Adults with overweight or obesity and metabolic dysfunction-associated steatotic liver disease had a more than 5% reduction in liver fat at 6 months with growth hormone therapy, according to findings from a randomized controlled trial.

A familial risk score comprised of age, obesity, type 2 diabetes and family history of nonalcoholic fatty liver disease accurately identified advanced fibrosis among first-degree relatives, according to researchers.

Type 2 diabetes was an independent predictor of hepatic decompensation and development of hepatocellular carcinoma among patients with nonalcoholic fatty liver disease, according to data.

Among patients with nonalcoholic steatohepatitis in the United States, 20% progressed to cirrhosis within 4 years, with female sex and nonsmoking status linked to lower risk for progression, according to data from the TARGET-NASH trial.

Modifying the timing of daily energy intake may improve metabolic health and restore natural circadian rhythms among patients with nonalcoholic fatty liver disease, according to a review published in Gut.